Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

SHA:688319 Revenue

In the year 2025, Chengdu Olymvax Biopharmaceuticals had annual revenue of 704.16M CNY with 19.58% growth. Chengdu Olymvax Biopharmaceuticals had revenue of 197.24M in the quarter ending December 31, 2025, a decrease of -2.46%.

• Revenue: 704.16M
• Revenue Growth: +19.58%
• P/S Ratio: 16.44
• Revenue / Employee: 1.50M
• Employees: 463
• Market Cap: 11.58B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	704.16M	115.30M	19.58%
Dec 31, 2024	588.86M	92.74M	18.69%
Dec 31, 2023	496.12M	-51.36M	-9.38%
Dec 31, 2022	547.48M	60.33M	12.38%
Dec 31, 2021	487.15M	167.04M	52.18%